Announcements Trials
Browse Landscape

Phase

Phase 2 108Phase 1 50Phase 1/2 43Phase 3 27Phase NA 2Phase 4 2Phase 2/3 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Leukemia 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Fatigue 1Congenital Abnormalities 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Dexamethasone 8daratumumab 5Lenalidomide 5Bortezomib 5Thalidomide 4Cyclophosphamide 4carfilzomib 2Melphalan 2Calcium Dobesilate 2trametinib 1tanespimycin 1pomalidomide 1fludarabine 1dabrafenib 1cobimetinib 1Whole-Body Irradiation 1Vemurafenib 1Stem Cell Transplantation 1Rivaroxaban 1Mesna 1MAGEA3 protein, human 1Lenograstim 1Human Growth Hormone 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Busulfan 1Bone Marrow Transplantation 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Multiple Myeloma × Calcium Dobesilate × Clear all
NCT07428369 2026-02-23

LINKER-MM8

Regeneron Pharmaceuticals

Phase 2/3 Not yet recruiting
1,570 enrolled
Plasma cell

Multiple Myeloma

NCT00038090 2018-10-31

Thalidomide-Dexamethasone for Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2/3 Completed
83 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡